Long-term safety study of bomedemstat for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been taking bomedemstat in a previous study for at least 6 months and it has been helping you.
- Your doctor must agree that you are still benefiting from bomedemstat and handling it well.
- You are not currently on a temporary break from the drug.
- You can swallow pills and follow dosing instructions at home.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
This trial tests a new combination of two drugs, bomedemstat and momelotinib, for people with myelofibrosis. It aims to see if adding bomedemstat can help when momelotinib alone isn't working well enough, or for those with low blood counts.
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This is an observational study that follows people with certain blood disorders. It aims to learn more about how these conditions behave in real life, which can help improve future care.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.